Symbols / KPTI Stock $9.08 +0.11% Karyopharm Therapeutics Inc.

Healthcare • Biotechnology • United States • NMS
KPTI (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Richard A. Paulson M.B.A.
Exch · Country NMS · United States
Market Cap 205.78M
Enterprise Value 410.35M
Income -194.97M
Sales 151.12M
FCF (ttm) —
Book/sh -11.78
Cash/sh 4.03
Employees 228
Insider 10d —
IPO Nov 06, 2013
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.86
PEG —
P/S 1.36
P/B -0.77
P/C —
EV/EBITDA -4.89
EV/Sales 2.71
Quick Ratio —
Current Ratio —
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -16.40
EPS next Y -4.89
EPS Growth —
Revenue Growth 16.80%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-11
Earnings (prior) 2026-05-14
ROA -40.62%
ROE —
ROIC —
Gross Margin 13.45%
Oper. Margin -76.31%
Profit Margin -129.02%
Shs Outstand 22.66M
Shs Float 14.70M
Insider Own 4.69%
Instit Own 83.71%
Short Float 23.40%
Short Ratio 12.69
Short Interest 5.28M
52W High 10.99
vs 52W High -17.38%
52W Low 3.65
vs 52W Low 148.77%
Beta 0.82
Impl. Vol. 1.59%
Rel Volume 0.29
Avg Volume 900.15K
Volume 257.56K
Target (mean) $13.50
Tgt Median $14.50
Tgt Low $7.00
Tgt High $16.00
# Analysts 6
Recom Buy
Prev Close $9.07
Price $9.08
Change 0.11%
About

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$13.50
Mean price target
2. Current target
$9.08
Latest analyst target
3. DCF / Fair value
$13.50
Proxy: analyst mean price target (no FCF/EPS data available).
Ratings
Current target
$9.08
Low
$7.00
High
$16.00
Mean
$13.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-06 main HC Wainwright & Co. Buy → Buy $13
2026-04-27 reit Piper Sandler Overweight → Overweight $16
2026-03-30 reit Piper Sandler Overweight → Overweight $8
2026-03-25 main Baird Outperform → Outperform $15
2026-03-25 main HC Wainwright & Co. Buy → Buy $8
2026-03-10 init Rodman & Renshaw — → Buy $28
2026-02-18 reit HC Wainwright & Co. Buy → Buy $15
2026-02-05 init Cantor Fitzgerald — → Overweight —
2025-11-04 main RBC Capital Outperform → Outperform $19
2025-10-13 up HC Wainwright & Co. Neutral → Buy $15
2025-10-09 reit Piper Sandler Overweight → Overweight $12
2025-10-09 main Baird Outperform → Outperform $21
2025-08-12 main Baird Outperform → Outperform $25
2025-07-16 down HC Wainwright & Co. Buy → Neutral —
2025-05-13 main RBC Capital Outperform → Outperform $33
2025-05-13 main Barclays Overweight → Overweight $10
2025-05-13 main Baird Outperform → Outperform $42
2025-03-03 main Baird Outperform → Outperform $54
2025-02-26 main HC Wainwright & Co. Buy → Buy $56
2025-02-20 reit RBC Capital Outperform → Outperform $3
News
RSS: Latest KPTI news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-21 BOHLIN GAREN G. Director — 15,508 $0.00 $0
2026-05-21 GREENE BARRY E Director — 15,508 $0.00 $0
2026-05-21 PAKIANATHAN DEEPIKA R Director — 15,508 $0.00 $0
2026-05-21 SCHOR CHEN Director — 15,508 $0.00 $0
2026-05-21 OLIGER CHRISTY J Director — 15,508 $0.00 $0
2026-05-21 SU ZHEN Director — 15,508 $0.00 $0
2026-05-14 PAULSON RICHARD A. Chief Executive Officer — 2,203 $9.50 $20,928
2026-05-14 RANGWALA RESHMA Officer — 408 $9.50 $3,876
2026-05-14 MANO MICHAEL Officer — 266 $9.50 $2,527
2026-05-14 CHENG SOHANYA ROSHAN Officer — 324 $9.50 $3,078
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
146.07
+0.57%
145.24
-0.55%
146.03
-7.03%
157.07
Operating Revenue
146.07
+0.57%
145.24
-0.55%
146.03
-7.03%
157.07
Cost Of Revenue
5.95
-0.97%
6.01
+21.55%
4.94
-5.20%
5.21
Reconciled Cost Of Revenue
5.95
-0.97%
6.01
+21.55%
4.94
-5.20%
5.21
Gross Profit
140.12
+0.64%
139.23
-1.32%
141.09
-7.09%
151.86
Operating Expense
230.82
-10.77%
258.67
-4.42%
270.63
-7.97%
294.06
Research And Development
125.62
-12.30%
143.23
+3.23%
138.75
-6.67%
148.66
Selling General And Administration
105.21
-8.86%
115.44
-12.47%
131.88
-9.30%
145.40
General And Administrative Expense
105.21
-8.86%
115.44
-12.47%
131.88
-9.30%
145.40
Salaries And Wages
61.34
-13.69%
71.07
-12.56%
81.28
-8.67%
88.99
Other Gand A
43.86
-1.14%
44.37
-12.32%
50.61
-10.29%
56.41
Total Expenses
236.77
-10.54%
264.68
-3.95%
275.57
-7.92%
299.28
Operating Income
-90.71
+24.06%
-119.44
+7.79%
-129.54
+8.90%
-142.20
Total Operating Income As Reported
-90.71
+24.06%
-119.44
+7.79%
-129.54
+8.90%
-142.20
EBITDA
-149.85
-288.18%
-38.60
+67.40%
-118.42
+14.99%
-139.31
Normalized EBITDA
-87.49
-5.02%
-83.31
+29.65%
-118.42
+14.99%
-139.31
Reconciled Depreciation
0.30
-12.94%
0.34
-35.85%
0.53
-14.65%
0.62
EBIT
-150.15
-285.56%
-38.94
+67.26%
-118.95
+14.99%
-139.93
Total Unusual Items
-62.37
-239.51%
44.70
0.00
0.00
Total Unusual Items Excluding Goodwill
-62.37
-239.51%
44.70
0.00
0.00
Special Income Charges
-62.37
-239.51%
44.70
0.00
0.00
Other Special Charges
62.37
+239.51%
-44.70
—
—
Net Income
-196.04
-156.52%
-76.42
+46.60%
-143.10
+13.43%
-165.29
Pretax Income
-196.00
-156.66%
-76.36
+46.51%
-142.78
+13.43%
-164.92
Net Non Operating Interest Income Expense
-43.08
-43.48%
-30.02
-133.09%
-12.88
+43.10%
-22.64
Interest Expense Non Operating
45.85
+22.52%
37.42
+57.08%
23.82
-4.69%
25.00
Net Interest Income
-43.08
-43.48%
-30.02
-133.09%
-12.88
+43.10%
-22.64
Interest Expense
45.85
+22.52%
37.42
+57.08%
23.82
-4.69%
25.00
Interest Income Non Operating
2.77
-62.53%
7.40
-32.38%
10.94
+363.88%
2.36
Interest Income
2.77
-62.53%
7.40
-32.38%
10.94
+363.88%
2.36
Other Income Expense
-62.21
-185.11%
73.10
+20633.71%
-0.36
-328.92%
-0.08
Other Non Operating Income Expenses
0.15
-99.46%
28.40
+8076.97%
-0.36
-328.92%
-0.08
Gain On Sale Of Security
—
—
—
-0.10
Tax Provision
0.04
-24.56%
0.06
-82.35%
0.32
-12.47%
0.37
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-13.10
-239.51%
9.39
0.00
0.00
Net Income Including Noncontrolling Interests
-196.04
-156.52%
-76.42
+46.60%
-143.10
+13.43%
-165.29
Net Income From Continuing Operation Net Minority Interest
-196.04
-156.52%
-76.42
+46.60%
-143.10
+13.43%
-165.29
Net Income From Continuing And Discontinued Operation
-196.04
-156.52%
-76.42
+46.60%
-143.10
+13.43%
-165.29
Net Income Continuous Operations
-196.04
-156.52%
-76.42
+46.60%
-143.10
+13.43%
-165.29
Normalized Income
-146.77
-31.35%
-111.74
+21.92%
-143.10
+13.43%
-165.29
Net Income Common Stockholders
-196.04
-156.52%
-76.42
+46.60%
-143.10
+13.43%
-165.29
Diluted EPS
-17.93
-28.53%
-13.95
+25.76%
-18.79
+37.99%
-30.30
Basic EPS
-17.93
-89.74%
-9.45
+49.71%
-18.79
+37.99%
-30.30
Basic Average Shares
10.94
+34.60%
8.12
+6.67%
7.62
+39.54%
5.46
Diluted Average Shares
10.94
+29.35%
8.45
+11.00%
7.62
+39.54%
5.46
Diluted NI Availto Com Stockholders
-196.04
-156.52%
-76.42
+46.60%
-143.10
+13.43%
-165.29
Line Item Trend 2023-12-31
Total Assets
240.44
Current Assets
233.92
Cash Cash Equivalents And Short Term Investments
191.44
Cash And Cash Equivalents
52.23
Other Short Term Investments
139.21
Receivables
26.96
Accounts Receivable
26.96
Inventory
3.04
Raw Materials
0.55
Work In Process
1.73
Finished Goods
0.76
Prepaid Assets
—
Restricted Cash
0.66
Other Current Assets
11.81
Total Non Current Assets
6.52
Net PPE
4.88
Gross PPE
11.45
Accumulated Depreciation
-6.57
Properties
0.00
Machinery Furniture Equipment
1.46
Other Properties
5.11
Leases
4.88
Investments And Advances
—
Other Non Current Assets
1.64
Total Liabilities Net Minority Interest
376.64
Current Liabilities
69.48
Payables And Accrued Expenses
48.01
Payables
3.12
Accounts Payable
3.12
Current Accrued Expenses
44.88
Pensionand Other Post Retirement Benefit Plans Current
16.51
Current Debt And Capital Lease Obligation
3.31
Current Debt
—
Other Current Borrowings
—
Current Capital Lease Obligation
3.31
Current Deferred Liabilities
—
Current Deferred Revenue
—
Other Current Liabilities
1.65
Total Non Current Liabilities Net Minority Interest
307.17
Long Term Debt And Capital Lease Obligation
173.71
Long Term Debt
170.92
Long Term Capital Lease Obligation
2.79
Non Current Deferred Liabilities
132.48
Other Non Current Liabilities
0.98
Stockholders Equity
-136.21
Common Stock Equity
-136.21
Capital Stock
0.01
Common Stock
0.01
Preferred Stock
0.00
Share Issued
7.66
Ordinary Shares Number
7.66
Treasury Shares Number
0.00
Additional Paid In Capital
1,350.98
Retained Earnings
-1,487.04
Gains Losses Not Affecting Retained Earnings
-0.16
Other Equity Adjustments
-0.16
Total Equity Gross Minority Interest
-136.21
Total Capitalization
34.71
Working Capital
164.44
Invested Capital
34.71
Total Debt
177.02
Net Debt
118.69
Capital Lease Obligations
6.10
Net Tangible Assets
-136.21
Tangible Book Value
-136.21
Derivative Product Liabilities
0.00
Interest Payable
13.45
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-75.37
+40.88%
-127.49
-37.49%
-92.72
+38.00%
-149.55
Cash Flow From Continuing Operating Activities
-75.37
+40.88%
-127.49
-37.49%
-92.72
+38.00%
-149.55
Net Income From Continuing Operations
-196.04
-156.52%
-76.42
+46.60%
-143.10
+13.43%
-165.29
Depreciation Amortization Depletion
0.30
-12.94%
0.34
-35.85%
0.53
-14.65%
0.62
Depreciation And Amortization
0.30
-12.94%
0.34
-35.85%
0.53
-14.65%
0.62
Other Non Cash Items
16.80
+163.84%
6.37
+682.43%
0.81
+0.25%
0.81
Stock Based Compensation
14.05
-23.75%
18.43
-15.12%
21.71
-38.67%
35.40
Asset Impairment Charge
—
—
—
—
Operating Gains Losses
61.66
+184.01%
-73.39
—
-0.28
Gain Loss On Investment Securities
-0.71
+97.54%
-28.69
—
-0.28
Change In Working Capital
28.27
+9461.59%
-0.30
-100.96%
31.42
+257.19%
-19.99
Change In Receivables
4.59
+220.61%
-3.80
-118.90%
20.12
+495.83%
-5.08
Changes In Account Receivables
4.59
+220.61%
-3.80
-118.90%
20.12
+495.83%
-5.08
Change In Inventory
0.70
+141.33%
-1.70
-243.61%
1.18
+1100.85%
-0.12
Change In Prepaid Assets
4.13
+1055.09%
-0.43
-106.47%
6.67
+215.43%
-5.78
Change In Payables And Accrued Expense
17.96
+190.36%
6.18
+42.12%
4.35
+152.02%
-8.37
Change In Accrued Expense
19.06
+353.77%
4.20
+4.97%
4.00
+141.97%
-9.54
Change In Payable
-1.10
-155.65%
1.98
+466.86%
0.35
-70.09%
1.17
Change In Account Payable
-1.10
-155.65%
1.98
+466.86%
0.35
-70.09%
1.17
Change In Other Working Capital
—
—
—
—
Change In Other Current Assets
1.34
+183.08%
-1.61
-181.96%
1.96
+16.99%
1.68
Change In Other Current Liabilities
-0.44
-141.60%
1.05
+136.66%
-2.87
-24.01%
-2.32
Investing Cash Flow
43.38
-54.57%
95.47
+1102.43%
7.94
+107.62%
-104.26
Cash Flow From Continuing Investing Activities
43.38
-54.57%
95.47
+1102.43%
7.94
+107.62%
-104.26
Net PPE Purchase And Sale
0.00
+100.00%
-0.14
0.00
+100.00%
-0.12
Purchase Of PPE
0.00
+100.00%
-0.14
0.00
+100.00%
-0.12
Capital Expenditure
—
-0.14
—
-0.12
Net Investment Purchase And Sale
43.38
-54.63%
95.61
+1104.22%
7.94
+107.62%
-104.14
Purchase Of Investment
0.00
+100.00%
-58.82
+63.04%
-159.15
+29.58%
-226.02
Sale Of Investment
43.38
-71.91%
154.44
-7.57%
167.09
+37.10%
121.88
Net Intangibles Purchase And Sale
—
—
0.00
0.00
Purchase Of Intangibles
—
—
0.00
0.00
Financing Cash Flow
30.05
-27.85%
41.65
+3605.16%
1.12
-99.42%
193.74
Cash Flow From Continuing Financing Activities
30.05
-27.85%
41.65
+3605.16%
1.12
-99.42%
193.74
Net Issuance Payments Of Debt
27.00
-67.59%
83.30
0.00
0.00
Issuance Of Debt
27.25
-67.29%
83.30
0.00
0.00
Repayment Of Debt
-0.25
0.00
0.00
—
Long Term Debt Issuance
27.25
-67.29%
83.30
0.00
0.00
Long Term Debt Payments
-0.25
0.00
0.00
—
Net Long Term Debt Issuance
27.00
-67.59%
83.30
0.00
0.00
Net Common Stock Issuance
8.75
0.00
0.00
-100.00%
189.76
Proceeds From Stock Option Exercised
0.76
-47.59%
1.45
+29.18%
1.12
-71.74%
3.98
Net Other Financing Charges
-6.46
+85.01%
-43.11
—
—
Changes In Cash
-1.94
-120.17%
9.63
+111.51%
-83.66
-39.26%
-60.07
Effect Of Exchange Rate Changes
0.02
+281.82%
-0.01
+67.65%
-0.03
+93.03%
-0.49
Beginning Cash Position
62.81
+18.09%
53.19
-61.14%
136.88
-30.67%
197.44
End Cash Position
60.89
-3.06%
62.81
+18.09%
53.19
-61.14%
136.88
Free Cash Flow
-75.37
+40.95%
-127.63
-37.64%
-92.72
+38.05%
-149.67
Interest Paid Supplemental Data
14.38
-62.74%
38.59
+81.81%
21.23
-38.38%
34.45
Amortization Of Securities
-0.41
+83.63%
-2.50
+38.90%
-4.10
-396.73%
-0.82
Common Stock Issuance
8.75
0.00
0.00
-100.00%
189.76
Issuance Of Capital Stock
8.75
0.00
0.00
-100.00%
189.76
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category